Faculty profile

Ian King

Back to faculty

Assistant ProfessorDepartment of Laboratory Medicine & PathobiologyUniversity of Toronto

Ian King

Assistant Professor

Department of Laboratory Medicine & Pathobiology

Temerty Faculty of Medicine

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Professors usually supervise graduate students in their department's programs.
8 publications in the last five years, latest in 2026.

These signals come from public records, including federal and provincial funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

128

Citations

Collaborators

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

University Profile

Search on Google Scholar

Search on ResearchGate

iDORCID OpenAlex

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their University of Toronto profile.

Latest papers

Real-world validation study of the LSC17 score for risk prediction in patients with newly diagnosed acute myeloid leukemia.
Haematologica · 2026
Genetic data sharing by clinical laboratories in Canada: A position statement by the Canadian College of Medical Geneticists.
American journal of human genetics · 2026
Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial.
Nature communications · 2026

All 11 publications

11 publications.

Real-world validation study of the LSC17 score for risk prediction in patients with newly diagnosed acute myeloid leukemia.

Murphy T, Zhang B, Zhang T, King I, Capo-Chichi J-M, Gupta V, Maze D, McNamara CJ, Minden MD, Schimmer AD

Haematologica20266 citationsOpen Access

DOI: 10.3324/haematol.2025.287777

Genetic data sharing by clinical laboratories in Canada: A position statement by the Canadian College of Medical Geneticists.

Lerner-Ellis J, Fisher Y, Zawati MH, Agatep R, Antonishyn N, Bosdet I, Boycott KM, King I, Lamont RE, Marshall CR, Martinez VD, Nelson TN, O'Rielly D, Yip S, Shantz B, Herscovich A, Price EM, Canadian College of Medical Geneticists,, Hartley T, Chun K

American journal of human genetics2026Open Access

DOI: 10.1016/j.ajhg.2026.09.001 PMID: 42772292

Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial.

Rose AAN, Maxwell J, Rousselle E, Mukonoweshuro CL, Elkholi IE, Riaud M, Biondini M, Cianfarano E, Soria-Bretones I, Tobin C, McGuire M, Law RWY, Elia AJ, Wang BX, King I, Zhang T, Pugh TJ, Kamil ZS, Butler M, Shepherd FA, Leighl NB, Razak AA, Hansen A, Saibil SD, Bedard PL, Siegel PM, Siu LL, Cescon DW, Spreafico A

Nature communications2026Open Access

DOI: 10.1038/s41467-025-68076-7 PMID: 41484121

Ulcerated CRTC1::TRIM11 cutaneous tumor with metastases.

Tseng C, Hein ECK, Smith SM, King I, Saibil S, Saeed Kamil Z

Journal of cutaneous pathology2024

DOI: 10.1111/cup.14669 PMID: 38877838

Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma.

Madariaga A, Garg S, Tchrakian N, Dhani NC, Jimenez W, Welch S, MacKay H, Ethier JL, Gilbert L, Li X, Rodriguez A, Chan L, Bowering V, Clarke B, Zhang T, King I, Downs G, Stockley T, Wang L, Udagani S, Oza AM, Lheureux S

Nature communications202328 citationsOpen Access

DOI: 10.1038/s41467-023-37084-w PMID: 36922497

A clinical laboratory-developed LSC17 stemness score assay for rapid risk assessment of patients with acute myeloid leukemia.

Ng SWK, Murphy T, King I, Zhang T, Mah M, Lu Z, Stickle N, Ibrahimova N, Arruda A, Mitchell A, Mai M, He R, Madala BS, Viswanatha DS, Dick JE, Chan S, Virtanen C, Minden MD, Mercer T, Stockley T, Wang JCY

Blood advances202228 citationsOpen Access

DOI: 10.1182/bloodadvances.2021005741 PMID: 34872104

A t(6;14;9)(p22;q22;q34) three‐way translocation: Description of a cytogenetically visible variant t(6;9) in acute myeloid leukemia

Adam C. Smith, Dawn C. Maze, Daniel Xia, José‐Mario Capo‐Chichi, Ian F. G. King, Hassan Abdulmaoula Sibai

American Journal of Hematology20225 citations

DOI: 10.1002/ajh.26534 PMID: 35292996

Turnaround Times in Melanoma BRAF Testing and the Impact on the Initiation of Systemic Therapy at a Single Tertiary Care Cancer Center.

Arteaga Ceballos DP, Saeed-Kamil Z, King I, Stockley T, Liu D, Muniz TP, Saibil SD, Hogg D, Spreafico A, Butler MO

JCO oncology practice20222 citationsOpen Access

DOI: 10.1200/op.21.00810 PMID: 35363503

Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.

Rose AAN, Armstrong SM, Hogg D, Butler MO, Saibil SD, Arteaga DP, Pimentel Muniz T, Kelly D, Ghazarian D, King I, Kamil ZS, Ross K, Spreafico A

Journal for immunotherapy of cancer202149 citationsOpen Access

DOI: 10.1136/jitc-2020-001642 PMID: 33483342

Development of a Metastatic Uveal Melanoma Prognostic Score (MUMPS) for Use in Patients Receiving Immune Checkpoint Inhibitors.

Kelly D, Rose AAN, Muniz TP, Hogg D, Butler MO, Saibil SD, King I, Kamil ZS, Ghazarian D, Ross K, Iafolla M, Araujo DV, Waldron J, Laperriere N, Krema H, Spreafico A

Cancers202110 citationsOpen Access

DOI: 10.3390/cancers13143640 PMID: 34298857

Profile data last refreshed on September 29, 2026 from the university directory, publication records and public research funding records.

Something wrong or missing on this profile? Suggest a correction

Ian King

Research

Latest papers

Real-world validation study of the LSC17 score for risk prediction in patients with newly diagnosed acute myeloid leukemia.

Genetic data sharing by clinical laboratories in Canada: A position statement by the Canadian College of Medical Geneticists.

Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial.

Ulcerated CRTC1::TRIM11 cutaneous tumor with metastases.

Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma.

A clinical laboratory-developed LSC17 stemness score assay for rapid risk assessment of patients with acute myeloid leukemia.

A t(6;14;9)(p22;q22;q34) three‐way translocation: Description of a cytogenetically visible variant t(6;9) in acute myeloid leukemia

Turnaround Times in Melanoma BRAF Testing and the Impact on the Initiation of Systemic Therapy at a Single Tertiary Care Cancer Center.

Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.

Development of a Metastatic Uveal Melanoma Prognostic Score (MUMPS) for Use in Patients Receiving Immune Checkpoint Inhibitors.

Frequent collaborators

Sam Saibil

Anna Spreafico

Tracy Stockley

Samuel Saibil

Jean Wang

Hassan Sibai

Dawn Maze

April Rose

Mark Minden

Steven Chan

José-Mario Capo-Chichi

Vikas Gupta

Josee Ethier

Christian Marshall

John Waldron

Mitchell Sabloff

Trevor Pugh

Josee-Lyne Ethier

Marcus Butler

Lillian Siu

Stephen Welch

Amit Oza

Ma'n Zawati

Stephanie Lheureux

Taila Hartley

Philippe Bedard

Adam Smith

Lisa Wang